Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million
July 27, 2020 20:48 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering
July 27, 2020 16:53 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 03, 2020 13:15 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
May 13, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346...
Allena Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Provides Business Update
March 16, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Streamlined URIROX-2 Design Potentially Reduces Target Length and Cost of Trial -- -- Regulatory Engagement on Registrational Path for Reloxaliase in High-Risk Enteric Hyperoxaluria (EH)...
Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference
February 24, 2020 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2, Second Pivotal Clinical Trial of Reloxaliase for Enteric Hyperoxaluria
February 12, 2020 07:00 ET
|
Allena Pharmaceuticals, Inc.
-- Reducing Target Enrollment to 200 Subjects ---- Conducting Earlier Interim Analysis, Expected in Q3 2021 ---- Company to Host Conference Call at 8:30 a.m. ET Today -- NEWTON, Mass., Feb. 12,...
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
December 04, 2019 17:00 ET
|
Allena Pharmaceuticals, Inc.
– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) – – Plan to Re-Engage with U.S. Food and Drug Administration (FDA) to Evaluate Opportunities to Streamline...
Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference
November 25, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...